Pfizer:   MAPK Inhibition in Melanoma
https://pfe-pfizercom-prod.s3.amazonaws.com/GMG_2020ONC4.pdf 

 Application Due Date: April 15, 2020

Specific Area of Interest: Projects that will be considered for Pfizer support will focus on increasing the understanding of MAPK pathway inhibitors and their use in the treatment of melanoma. Topics of interest include:

• *             Mechanism of action of targeted therapy
• *             Incorporating BRAF biomarkers and genomic testing into community practice
• *             Increasing understanding of recent clinical data to help inform the selection of treatment options
• *             Monitoring for and managing side effects of therapies
• *             Exploring the management of special population metastatic melanoma patients
• *             Development of or access to patient resources to help improve patient understanding